

# company announcement

## Novo Nordisk A/S – Share repurchase programme

**Bagsværd, Denmark, 1 October 2014** – On 7 August 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.

Under the programme initiated 7 August 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.5 billion in the period from 7 August 2014 to 28 October 2014.

Since the announcement as of 22 September 2014, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
<b>Accumulated, last announcement</b>	<b>7,212,000</b>		<b>1,865,968,911</b>
22 September 2014	225,000	280.31	63,069,795
23 September 2014	230,000	277.37	63,794,042
24 September 2014	210,000	277.32	58,236,906
25 September 2014	228,000	280.09	63,859,562
26 September 2014	190,000	280.94	53,378,923
29 September 2014	190,000	282.30	53,636,069
30 September 2014	210,000	282.03	59,225,712
<b>Accumulated under the programme</b>	<b>8,695,000</b>		<b>2,281,169,921</b>

With the transactions stated above, Novo Nordisk owns a total of 43,276,289 B shares of DKK 0.20, corresponding to 1.6% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 30 September 2014, Novo Nordisk has repurchased a total of 40,432,995 B shares equal to a transaction value of DKK 9,985,688,420.

*Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

### **Further information**

#### *Media:*

Anne Margrethe Hauge	+45 4442 3450	<a href="mailto:amhg@novonordisk.com">amhg@novonordisk.com</a>
----------------------	---------------	--

#### *Investors:*

Kasper Roseeuw Poulsen	+45 3079 4303	<a href="mailto:krop@novonordisk.com">krop@novonordisk.com</a>
Jannick Lindegaard Denholt	+45 3079 8519	<a href="mailto:jlis@novonordisk.com">jlis@novonordisk.com</a>
Daniel Bohsen	+45 3079 6376	<a href="mailto:dabo@novonordisk.com">dabo@novonordisk.com</a>
Frank Daniel Mersebach (US)	+1 609 235 8567	<a href="mailto:fdni@novonordisk.com">fdni@novonordisk.com</a>